Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.61 |
| ▸ | ACACB | O00763 | 1/20 | 0.59 |
| ▸ | ACACA | Q13085 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3279650 | 1.00 | ACLY (0.61) | ACLYACACBACACAMAPTKMT2A | |
| SCHEMBL3291351 | 1.00 | ACLY (0.61) | ACLYACACBACACAMAPTKMT2A | |
| SCHEMBL3286285 | 1.00 | ACLY (0.61) | ACLYACACBACACAMAPTKMT2A | |
| SCHEMBL3281521 | 0.98 | ACLY (0.57) | ACLYACACBACACAMAPTKMT2A | |
| SCHEMBL209070 | 0.95 | ACLY (0.55) | ACLYACACBACACAMAPTKMT2A | |
| SCHEMBL13302051 | 0.94 | ACLY (0.55) | ACLYACACBACACAMAPTKMT2A | |
| SCHEMBL16375048 | 0.92 | ACLY (0.53) | ACLYACACBACACAMAPTKMT2A | |
| SCHEMBL16375055 | 0.92 | ACLY (0.53) | ACLYACACBACACAMAPTKMT2A | |
| SCHEMBL187235 | 0.92 | KMT2A (0.53) | ACLYACACBACACAMAPTKMT2A | |
| SCHEMBL13302052 | 0.92 | ACLY (0.53) | ACLYACACBACACAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907204-B | Synthesis method of bevacizidine acid | 苏州特瑞药业股份有限公司 | 2024-08-16 | — | — | CN | claimed |
| WO-2023187833-A1 | A NOVEL SALT OF BEMPEDOIC ACID | ENALTEC LABS PRIVATE LIMITED (IN) | 2023-10-05 | — | — | WO | claimed |
| CN-114436821-A | Crystallization method of pipadiric acid intermediate | 甘李药业股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-111170855-A | Compound and method for synthesizing 8-hydroxy-2, 2,14, 14-tetramethylpentadecanedioic acid by using same | 奥锐特药业(天津)有限公司 | 2020-05-19 | — | — | CN | claimed |
| EP-1564200-A1 | Ketone compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| US-6699910-B2 | TREATING AND PREVENTING CARDIOVASCULAR DISEASES, DYSLIPIDEMIAS, AND GLUCOSE METABOLISM AS HYPOGLYCEMIC AGENTS, USE TO REDUCE THE FAT CONTENT OF MEAT IN LIVESTOCK AND REDUCE THE CHOLESTEROL CONTENT OF EGGS | ESPERION THERAPEUTICS, INC. | 2004-03-02 | — | — | US | claimed |
| EP-1326822-A2 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| US-20030078239-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2003-04-24 | — | — | US | claimed |
| WO-2002030860-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2003-02-20 | — | — | WO | claimed |
| WO-2002030860-A2 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| CN-116924886-B | Synthesis method of 8-oxo-2,2,14,14-tetramethyl pentadecanedioic acid | 武汉武药科技有限公司 | 2025-08-29 | — | — | CN | disclosed |
| WO-2025092475-A1 | SYNTHESIS METHOD FOR BEMPEDOIC ACID AND BEMPEDOIC ACID INTERMEDIATE, AND BEMPEDOIC ACID INTERMEDIATE | 扬州奥锐特药业有限公司 | 2025-05-08 | — | — | WO | disclosed |
| CN-119930422-A | Preparation method of bevacizidine acid and intermediate thereof | 扬州奥锐特药业有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119161243-A | Preparation method of bevacizidine acid | 山西库邦生物医药科技有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-114907204-B | Synthesis method of bevacizidine acid | 苏州特瑞药业股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2004067489-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| US-6699910-B2 | TREATING AND PREVENTING CARDIOVASCULAR DISEASES, DYSLIPIDEMIAS, AND GLUCOSE METABOLISM AS HYPOGLYCEMIC AGENTS, USE TO REDUCE THE FAT CONTENT OF MEAT IN LIVESTOCK AND REDUCE THE CHOLESTEROL CONTENT OF EGGS | ESPERION THERAPEUTICS, INC. | 2004-03-02 | — | — | US | disclosed |
| EP-1326822-A2 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030860-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002030860-A2 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078239-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | ACLY 358/4885ACACB 91/4885ACACA 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.